Last reviewed · How we verify
Estrobene (DIETHYLSTILBESTROL)
Estrobene (generic name: DIETHYLSTILBESTROL) is a Standardized Chemical Allergen [EPC] Small molecule drug developed by Tablicaps. It is currently FDA-approved (first approved 1973).
Estrobene is a small molecule with the synonyms DIBESTIL, DIETHYLSTILBESTROL DIPROPIONATE, and DIETHYLSTILBESTROL PROPIONATE. It has been studied in clinical trials for various conditions, including Hormone Refractory Prostate Cancer, Bone Metastases, Migraine Headache, and Overactive Bladder, but the specific indications are not clearly stated in the provided facts.
At a glance
| Generic name | DIETHYLSTILBESTROL |
|---|---|
| Sponsor | Tablicaps |
| Drug class | Standardized Chemical Allergen [EPC] |
| Target | Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
Common side effects
Drug interactions
- fosphenytoin
- letrozole
- phenobarbital
- phenytoin
Key clinical trials
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (PHASE3)
- A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
- Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy (PHASE2)
- Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. (PHASE3)
- Ibudilast in the Treatment of Patients With Chronic Migraine. (PHASE1)
- Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer (PHASE3)
- Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estrobene CI brief — competitive landscape report
- Estrobene updates RSS · CI watch RSS
- Tablicaps portfolio CI
Frequently asked questions about Estrobene
What is Estrobene?
Who makes Estrobene?
What is the generic name of Estrobene?
What drug class is Estrobene in?
When was Estrobene approved?
What development phase is Estrobene in?
What does Estrobene target?
Related
- Drug class: All Standardized Chemical Allergen [EPC] drugs
- Target: All drugs targeting Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3
- Manufacturer: Tablicaps — full pipeline
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing